--- title: "Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/286240587.md" description: "Analyst Andres Y. Maldonado from H.C. Wainwright has reiterated a Buy rating on Zentalis Pharmaceuticals, maintaining a price target of $10. The rating is based on Zentalis’ advancements with azenosertib and its WEE1-focused strategy, including a 400mg once-daily dosing regimen supported by positive interim DENALI data. The company aims to position azenosertib as a targeted treatment for Cyclin E1-positive platinum-resistant ovarian cancer patients. With a cash balance of approximately $212M, Zentalis is well-positioned for upcoming catalysts, justifying the price target and rating." datetime: "2026-05-13T10:20:07.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286240587.md) - [en](https://longbridge.com/en/news/286240587.md) - [zh-HK](https://longbridge.com/zh-HK/news/286240587.md) --- # Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts Analyst Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Zentalis Pharmaceuticals and keeping the price target at $10.00. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Andres Y. Maldonado has given his Buy rating due to a combination of factors tied to Zentalis’ progress with azenosertib and its WEE1-focused strategy. He highlights that the company has now locked in a 400mg once-daily 5:2 dosing regimen, supported by interim DENALI data showing stronger responses than the lower dose, a manageable safety profile, and fewer discontinuations, which together de-risk the dose-selection overhang and set up a more binary, value-defining readout in late 2026. Maldonado also underscores that DENALI and the newly launched ASPENOVA Phase 3 trial could position azenosertib as the first oral, non-chemotherapy targeted treatment for a sizable subset of Cyclin E1-positive platinum-resistant ovarian cancer patients, a population with poor outcomes and no approved targeted options today. He notes that ongoing combination work in the MUIR study adds upside optionality, while a cash balance of roughly $212M extending into late 2027 supports execution through these key catalysts, justifying the unchanged $10 price target and Buy rating. Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Verastem, and CG Oncology, Inc.. According to TipRanks, Y. Maldonado has an average return of 42.1% and a 55.08% success rate on recommended stocks. ### Related Stocks - [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md) - [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md) - [CGON.US](https://longbridge.com/en/quote/CGON.US.md) ## Related News & Research - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md) - [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md) - [Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study](https://longbridge.com/en/news/287053007.md)